CO2018009559A2 - Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue - Google Patents

Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue

Info

Publication number
CO2018009559A2
CO2018009559A2 CONC2018/0009559A CO2018009559A CO2018009559A2 CO 2018009559 A2 CO2018009559 A2 CO 2018009559A2 CO 2018009559 A CO2018009559 A CO 2018009559A CO 2018009559 A2 CO2018009559 A2 CO 2018009559A2
Authority
CO
Colombia
Prior art keywords
dengue viral
indole derivatives
inhibitors
compounds
viral replication
Prior art date
Application number
CONC2018/0009559A
Other languages
English (en)
Inventor
Pierre Jean-Marie Bernard Raboisson
Bart Rudolf Romanie Kesteleyn
Arnaud Didier M Marchand
Jean-François Bonfanti
Dorothée Alice Marie-Eve Bardiot
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of CO2018009559A2 publication Critical patent/CO2018009559A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a derivados de indol sustituidos, a métodos para prevenir o tratar infecciones víricas por dengue mediante el uso de dichos compuestos y también se refiere a dichos compuestos para su uso como medicamento, más preferiblemente, para su uso como medicamento para tratar o prevenir infecciones víricas por dengue. La presente invención se refiere además a composiciones farmacéuticas o preparados combinados de los compuestos, a las composiciones o preparados para su uso como un medicamento, más preferiblemente para la prevención o el tratamiento de infecciones víricas por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
CONC2018/0009559A 2016-03-31 2017-03-31 Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue CO2018009559A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163312 2016-03-31
PCT/EP2017/057660 WO2017167950A1 (en) 2016-03-31 2017-03-31 Substituted indole derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
CO2018009559A2 true CO2018009559A2 (es) 2018-09-20

Family

ID=55650292

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0009559A CO2018009559A2 (es) 2016-03-31 2017-03-31 Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue

Country Status (26)

Country Link
US (1) US10646469B2 (es)
EP (1) EP3436435B1 (es)
JP (1) JP6888021B2 (es)
KR (1) KR102359743B1 (es)
CN (1) CN108884033B (es)
AU (1) AU2017242893A1 (es)
BR (1) BR112018068676A2 (es)
CA (1) CA3013405A1 (es)
CL (1) CL2018002729A1 (es)
CO (1) CO2018009559A2 (es)
CR (1) CR20180495A (es)
DK (1) DK3436435T3 (es)
EA (1) EA201892214A1 (es)
EC (1) ECSP18073245A (es)
ES (1) ES2882488T3 (es)
HK (1) HK1258142A1 (es)
HR (1) HRP20210847T1 (es)
HU (1) HUE054936T2 (es)
IL (1) IL261944A (es)
LT (1) LT3436435T (es)
MX (1) MX2018011784A (es)
PH (1) PH12018502015A1 (es)
SG (1) SG11201808138YA (es)
SI (1) SI3436435T1 (es)
WO (1) WO2017167950A1 (es)
ZA (1) ZA201806473B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue
PE20200604A1 (es) 2017-05-22 2020-03-10 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
WO2024178504A1 (en) * 2023-02-27 2024-09-06 Enveric Biosciences Canada Inc. Tri-halo-alkoxy-substituted tryptamine derivatives and methods of using

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Hsp90阻害活性を有するプリン類似体
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US20060211698A1 (en) 2005-01-14 2006-09-21 Genelabs, Inc. Bicyclic heteroaryl derivatives for treating viruses
US20060194835A1 (en) 2005-02-09 2006-08-31 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
MX338530B (es) 2008-06-03 2016-04-21 Siga Technologies Inc Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
WO2010021878A1 (en) 2008-08-19 2010-02-25 Janssen Pharmaceutica Nv Cold menthol receptor antagonists
EP2393359A4 (en) * 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
EP2523951B1 (en) 2010-01-15 2015-04-22 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
ES2655518T3 (es) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
RS57659B1 (sr) 2014-01-31 2018-11-30 Bristol Myers Squibb Co Makrociklusi sa heterocikličnim p2' grupama kao inhibitori faktora xia
NO2721243T3 (es) 2014-10-01 2018-10-20
WO2016050841A1 (en) 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
RS58394B1 (sr) 2014-10-01 2019-04-30 Janssen Pharmaceuticals Inc Mono- ili di-supstituisani indoli kao inhibitori replikacije denga virusa
JOP20150335B1 (ar) 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6864001B2 (ja) 2015-11-03 2021-04-21 ゾエティス・サービシーズ・エルエルシー ゾル−ゲルポリマー組成物及びそれらの使用
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
DK3436444T3 (da) 2016-03-31 2020-07-27 Takeda Pharmaceuticals Co Heterocyklisk forbindelse
ES2930058T3 (es) 2016-04-01 2022-12-05 Kite Pharma Inc Receptores quiméricos y métodos de uso de los mismos
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
PL3436457T3 (pl) 2016-04-01 2022-11-28 Basf Se Związki bicykliczne
IL296966A (en) 2016-04-01 2022-12-01 Amgen Inc Chimeric flt-3 receptors and methods of using them
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017173206A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue
PE20200604A1 (es) 2017-05-22 2020-03-10 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Also Published As

Publication number Publication date
ES2882488T3 (es) 2021-12-02
HUE054936T2 (hu) 2021-10-28
HK1258142A1 (zh) 2019-11-08
JP2019510024A (ja) 2019-04-11
US20190274999A1 (en) 2019-09-12
EA201892214A1 (ru) 2019-03-29
SG11201808138YA (en) 2018-10-30
PH12018502015A1 (en) 2019-07-15
ZA201806473B (en) 2020-05-27
US10646469B2 (en) 2020-05-12
MX2018011784A (es) 2019-02-13
CL2018002729A1 (es) 2018-11-23
DK3436435T3 (da) 2021-08-09
KR102359743B1 (ko) 2022-02-07
AU2017242893A1 (en) 2018-08-09
CR20180495A (es) 2018-12-06
LT3436435T (lt) 2021-08-25
ECSP18073245A (es) 2018-10-31
JP6888021B2 (ja) 2021-06-16
CN108884033A (zh) 2018-11-23
BR112018068676A2 (pt) 2019-01-15
KR20180130498A (ko) 2018-12-07
CN108884033B (zh) 2021-03-09
WO2017167950A1 (en) 2017-10-05
EP3436435B1 (en) 2021-05-12
HRP20210847T1 (hr) 2021-07-23
EP3436435A1 (en) 2019-02-06
SI3436435T1 (sl) 2021-08-31
IL261944A (en) 2018-10-31
CA3013405A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
CO2018009559A2 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue